Graphite Bio Competitors and Similar CompaniesClear all
Graphite Bio's competitors and similar companies include Asklepios BioPharmaceutical, ProQR Therapeutics, Ambrx and Precigen.
 Graphite Bio Graphite Bio is a gene-editing company focused on the development of therapies for patients suffering from life-threatening genetic diseases. |  Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein. |  ProQR Therapeutics ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases. |  Ambrx Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code. |  Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. | |
Founding Date | Founding Date 2017 | Founding Date 2001 | Founding Date 2012 | Founding Date 2003 | Founding Date 1998 |
Type | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations South San Francisco, US HQ | Locations Chapel Hill, US HQ Roslin, GB | Locations Leiden, NL HQ Cambridge, US | Locations San Diego, US HQ | Locations Germantown, US HQ Gent, BE Sioux Center, US |
Employees | Employees 27 | Employees 5172% increase | Employees 166 | Employees 70 | Employees 601 |
Valuation ($) | Valuation ($) 185.2 m | Valuation ($) N/A | Valuation ($) 281.8 m | Valuation ($) 1.8 b | Valuation ($) 246.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $19.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) €15.9m (FY, 2025) | Revenue (est.) $7.4m (FY, 2022) | Revenue (est.) $9.7m (FY, 2025) |
Cost of goods | Cost of goods $418k (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $18.7m (FY, 2025) | Gross profit N/A | Gross profit €16.3m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($82.1m) (FY, 2025) | Net income N/A | Net income (€42.2m) (FY, 2025) | Net income ($78m) (FY, 2022) | Net income ($250.6m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 235m | Total funding raised $ 57.8m | Total funding raised $ 347.9m | Total funding raised $ 379m |
For sources of this data, please see the company profile
View Company Profiles
Asklepios BioPharmaceutical
HQ
Chapel Hill, US
Employees
517↑ 2% increase
Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.
View companyProQR Therapeutics
HQ
Leiden, NL
Employees
166
ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases.
View companyAmbrx
HQ
San Diego, US
Employees
70
Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code.
View companyPrecigen
HQ
Germantown, US
Employees
601
Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View company